Select Language:
In a recent statement, officials from ByteDance’s Seed team addressed the news surrounding Gu Quanquan’s departure. They clarified that Gu was not involved in the AI pharmaceutical division or managing pre-training initiatives within the company. The team emphasized that his resignation was part of individual career decisions and does not impact their ongoing projects in AI or related fields. As ByteDance continues to develop its technological capabilities, the company reassures stakeholders that its core focus remains on innovative AI research and product development.




